| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Scleroderma, Systemic | 41 | 2021 | 583 | 11.21 | Why? |
| Heart Failure | 126 | 2021 | 6638 | 10.98 | Why? |
| Stroke Volume | 33 | 2021 | 2153 | 4.57 | Why? |
| Relaxin | 8 | 2019 | 25 | 2.93 | Why? |
| Disease Management | 18 | 2020 | 6841 | 2.44 | Why? |
| Raynaud Disease | 6 | 2019 | 86 | 2.40 | Why? |
| Skin Ulcer | 8 | 2018 | 98 | 2.31 | Why? |
| Tetrazoles | 5 | 2019 | 262 | 2.09 | Why? |
| Aminobutyrates | 3 | 2019 | 142 | 2.00 | Why? |
| Mineralocorticoid Receptor Antagonists | 6 | 2020 | 203 | 1.94 | Why? |
| Neovascularization, Pathologic | 5 | 2019 | 305 | 1.82 | Why? |
| Aorta | 3 | 2019 | 355 | 1.76 | Why? |
| Cardiomyopathies | 7 | 2021 | 997 | 1.72 | Why? |
| Vasodilator Agents | 7 | 2019 | 344 | 1.69 | Why? |
| Heart Ventricles | 7 | 2019 | 1139 | 1.59 | Why? |
| Diuretics | 5 | 2019 | 326 | 1.58 | Why? |
| Peripheral Vascular Diseases | 3 | 2019 | 133 | 1.49 | Why? |
| Heart-Assist Devices | 6 | 2019 | 812 | 1.43 | Why? |
| Peripartum Period | 2 | 2018 | 89 | 1.39 | Why? |
| Diagnostic Techniques, Cardiovascular | 3 | 2018 | 144 | 1.38 | Why? |
| Cardiotonic Agents | 4 | 2018 | 418 | 1.35 | Why? |
| Exercise Tolerance | 5 | 2019 | 634 | 1.35 | Why? |
| Natriuretic Peptide, Brain | 11 | 2020 | 1215 | 1.34 | Why? |
| Connective Tissue Diseases | 2 | 2021 | 187 | 1.33 | Why? |
| Cardiomyopathy, Dilated | 3 | 2019 | 251 | 1.32 | Why? |
| Atrial Fibrillation | 9 | 2021 | 2320 | 1.29 | Why? |
| Iloprost | 4 | 2019 | 38 | 1.28 | Why? |
| Vascular Stiffness | 3 | 2018 | 264 | 1.25 | Why? |
| Biomarkers | 34 | 2019 | 23361 | 1.25 | Why? |
| Diagnostic Imaging | 3 | 2019 | 1044 | 1.24 | Why? |
| Ventricular Function, Left | 12 | 2020 | 1555 | 1.18 | Why? |
| Hemodynamics | 8 | 2019 | 1562 | 1.18 | Why? |
| Acute Disease | 33 | 2020 | 6029 | 1.12 | Why? |
| Scleroderma, Diffuse | 6 | 2018 | 20 | 1.11 | Why? |
| Ventricular Remodeling | 5 | 2018 | 349 | 1.10 | Why? |
| Angiotensin Receptor Antagonists | 9 | 2021 | 3892 | 1.08 | Why? |
| Mitral Valve Insufficiency | 5 | 2019 | 302 | 1.05 | Why? |
| Cardiology | 7 | 2020 | 2873 | 1.04 | Why? |
| Hypertension, Pulmonary | 8 | 2018 | 970 | 1.03 | Why? |
| Cardiovascular Agents | 7 | 2017 | 663 | 0.98 | Why? |
| Clinical Trials as Topic | 14 | 2020 | 7330 | 0.95 | Why? |
| Adrenergic beta-Antagonists | 5 | 2018 | 465 | 0.95 | Why? |
| Xanthines | 3 | 2018 | 27 | 0.93 | Why? |
| Endothelial Cells | 7 | 2019 | 2048 | 0.90 | Why? |
| Benzazepines | 2 | 2018 | 49 | 0.88 | Why? |
| Heart Rupture, Post-Infarction | 1 | 2020 | 74 | 0.84 | Why? |
| Prognosis | 46 | 2021 | 32490 | 0.84 | Why? |
| Echocardiography, Doppler | 4 | 2018 | 269 | 0.84 | Why? |
| Heart Aneurysm | 1 | 2020 | 46 | 0.83 | Why? |
| Heart Transplantation | 8 | 2020 | 1293 | 0.82 | Why? |
| Ventricular Dysfunction, Left | 5 | 2020 | 993 | 0.81 | Why? |
| Humans | 233 | 2021 | 930598 | 0.81 | Why? |
| Sprains and Strains | 1 | 2019 | 21 | 0.79 | Why? |
| Lung Diseases, Interstitial | 6 | 2020 | 1476 | 0.78 | Why? |
| Neovascularization, Physiologic | 2 | 2017 | 160 | 0.77 | Why? |
| Arrhythmogenic Right Ventricular Dysplasia | 1 | 2019 | 56 | 0.77 | Why? |
| Animal Assisted Therapy | 1 | 2018 | 19 | 0.75 | Why? |
| Receptors, Formyl Peptide | 1 | 2018 | 26 | 0.74 | Why? |
| Skin | 9 | 2018 | 2096 | 0.74 | Why? |
| Echocardiography | 15 | 2020 | 3661 | 0.73 | Why? |
| Cardiac Resynchronization Therapy | 2 | 2018 | 191 | 0.73 | Why? |
| Neuroticism | 1 | 2018 | 87 | 0.73 | Why? |
| Atrial Function, Left | 1 | 2019 | 82 | 0.72 | Why? |
| Microvessels | 3 | 2017 | 490 | 0.72 | Why? |
| Societies, Medical | 6 | 2020 | 6907 | 0.72 | Why? |
| Heart Valve Prosthesis Implantation | 4 | 2019 | 552 | 0.72 | Why? |
| Heart Failure, Systolic | 1 | 2018 | 39 | 0.71 | Why? |
| Synovial Membrane | 1 | 2017 | 72 | 0.70 | Why? |
| Quality of Health Care | 3 | 2019 | 1948 | 0.70 | Why? |
| Hospitalization | 24 | 2021 | 54280 | 0.70 | Why? |
| Comorbidity | 23 | 2021 | 34796 | 0.67 | Why? |
| Pregnancy Complications, Cardiovascular | 2 | 2019 | 231 | 0.66 | Why? |
| Patient Readmission | 8 | 2018 | 1543 | 0.66 | Why? |
| Infliximab | 1 | 2021 | 502 | 0.66 | Why? |
| Pulmonary Wedge Pressure | 1 | 2017 | 53 | 0.65 | Why? |
| Morbidity | 8 | 2019 | 1426 | 0.65 | Why? |
| Troponin T | 4 | 2020 | 771 | 0.65 | Why? |
| Fibroblasts | 2 | 2018 | 839 | 0.65 | Why? |
| Glycocalyx | 1 | 2017 | 110 | 0.64 | Why? |
| Osteonecrosis | 1 | 2017 | 55 | 0.64 | Why? |
| Heart Diseases | 5 | 2020 | 3503 | 0.64 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 6 | 2020 | 5277 | 0.63 | Why? |
| Cell Adhesion Molecules, Neuronal | 1 | 2015 | 12 | 0.63 | Why? |
| Semaphorins | 1 | 2015 | 12 | 0.62 | Why? |
| Pericardial Effusion | 1 | 2020 | 312 | 0.62 | Why? |
| Glucuronidase | 1 | 2017 | 103 | 0.62 | Why? |
| Pulmonary Circulation | 1 | 2018 | 207 | 0.62 | Why? |
| Angiotensin II Type 1 Receptor Blockers | 2 | 2018 | 520 | 0.61 | Why? |
| Creatinine | 3 | 2020 | 1443 | 0.61 | Why? |
| Receptor, Angiotensin, Type 2 | 1 | 2017 | 190 | 0.60 | Why? |
| Aorta, Thoracic | 1 | 2018 | 271 | 0.59 | Why? |
| Receptors, Urokinase Plasminogen Activator | 1 | 2018 | 252 | 0.59 | Why? |
| Maltose | 3 | 2020 | 50 | 0.58 | Why? |
| Blood Pressure | 9 | 2019 | 2198 | 0.58 | Why? |
| Edema, Cardiac | 2 | 2019 | 33 | 0.57 | Why? |
| Sjogren's Syndrome | 1 | 2018 | 284 | 0.56 | Why? |
| Disease Progression | 19 | 2021 | 13580 | 0.56 | Why? |
| Patient Selection | 8 | 2020 | 4560 | 0.56 | Why? |
| Infusions, Intravenous | 5 | 2019 | 1224 | 0.56 | Why? |
| Cardiovascular Diseases | 8 | 2020 | 11497 | 0.56 | Why? |
| Pericarditis | 1 | 2020 | 417 | 0.56 | Why? |
| Heart Valve Diseases | 1 | 2019 | 355 | 0.55 | Why? |
| Epithelial-Mesenchymal Transition | 1 | 2017 | 242 | 0.54 | Why? |
| Neuropilin-1 | 1 | 2017 | 284 | 0.54 | Why? |
| Renin-Angiotensin System | 5 | 2021 | 3661 | 0.54 | Why? |
| Pulmonary Edema | 3 | 2019 | 430 | 0.54 | Why? |
| Female | 120 | 2021 | 380317 | 0.53 | Why? |
| Ferric Compounds | 3 | 2020 | 136 | 0.52 | Why? |
| Survival Rate | 22 | 2019 | 9206 | 0.52 | Why? |
| Aged | 91 | 2021 | 215776 | 0.51 | Why? |
| Blood Vessels | 1 | 2015 | 228 | 0.51 | Why? |
| Pain | 2 | 2018 | 1084 | 0.51 | Why? |
| Endothelium | 1 | 2017 | 460 | 0.51 | Why? |
| Male | 117 | 2021 | 367725 | 0.50 | Why? |
| Valsartan | 3 | 2019 | 206 | 0.50 | Why? |
| Biphenyl Compounds | 3 | 2019 | 249 | 0.50 | Why? |
| Double-Blind Method | 14 | 2020 | 5988 | 0.50 | Why? |
| Pulmonary Embolism | 3 | 2021 | 4775 | 0.50 | Why? |
| Vascular Endothelial Growth Factor A | 1 | 2017 | 604 | 0.49 | Why? |
| Diet, Mediterranean | 1 | 2017 | 351 | 0.49 | Why? |
| Evidence-Based Medicine | 4 | 2019 | 3228 | 0.49 | Why? |
| Heart Function Tests | 3 | 2019 | 101 | 0.49 | Why? |
| Heart | 4 | 2018 | 1791 | 0.49 | Why? |
| Systole | 6 | 2018 | 252 | 0.49 | Why? |
| Risk Assessment | 17 | 2021 | 25439 | 0.48 | Why? |
| ST Elevation Myocardial Infarction | 5 | 2020 | 3051 | 0.47 | Why? |
| Endpoint Determination | 3 | 2018 | 344 | 0.46 | Why? |
| Reactive Oxygen Species | 1 | 2018 | 1136 | 0.46 | Why? |
| Global Health | 14 | 2020 | 13911 | 0.46 | Why? |
| Arthritis, Rheumatoid | 4 | 2017 | 2043 | 0.46 | Why? |
| Middle Aged | 84 | 2021 | 270681 | 0.45 | Why? |
| Myocardium | 3 | 2021 | 2323 | 0.45 | Why? |
| Disability Evaluation | 4 | 2018 | 671 | 0.44 | Why? |
| Phenotype | 6 | 2020 | 4037 | 0.44 | Why? |
| Primary Prevention | 1 | 2018 | 778 | 0.43 | Why? |
| Cause of Death | 9 | 2019 | 4823 | 0.42 | Why? |
| Interpersonal Relations | 1 | 2018 | 926 | 0.42 | Why? |
| Obesity | 4 | 2019 | 7388 | 0.42 | Why? |
| Recombinant Proteins | 8 | 2019 | 3786 | 0.42 | Why? |
| Treatment Outcome | 39 | 2020 | 51732 | 0.42 | Why? |
| Proteomics | 2 | 2018 | 2481 | 0.42 | Why? |
| Insulin | 1 | 2019 | 1316 | 0.41 | Why? |
| Kidney Diseases | 3 | 2019 | 1434 | 0.41 | Why? |
| Fibrosis | 4 | 2017 | 800 | 0.41 | Why? |
| Multiple Organ Failure | 1 | 2020 | 1724 | 0.41 | Why? |
| Defibrillators, Implantable | 1 | 2017 | 624 | 0.41 | Why? |
| Europe | 20 | 2020 | 12702 | 0.40 | Why? |
| Oligopeptides | 3 | 2018 | 576 | 0.40 | Why? |
| Medication Adherence | 1 | 2019 | 1270 | 0.39 | Why? |
| Scleroderma, Limited | 2 | 2018 | 10 | 0.39 | Why? |
| Glucocorticoids | 3 | 2021 | 4431 | 0.39 | Why? |
| Follow-Up Studies | 23 | 2020 | 17020 | 0.38 | Why? |
| Cystic Fibrosis | 1 | 2019 | 1104 | 0.38 | Why? |
| Aspirin | 1 | 2017 | 1043 | 0.38 | Why? |
| Hospital Mortality | 12 | 2021 | 22087 | 0.38 | Why? |
| Cardiologists | 3 | 2018 | 366 | 0.38 | Why? |
| Ferritins | 2 | 2017 | 2055 | 0.37 | Why? |
| Patient Education as Topic | 4 | 2019 | 1476 | 0.37 | Why? |
| Peptide Fragments | 5 | 2020 | 2075 | 0.37 | Why? |
| Sodium Potassium Chloride Symporter Inhibitors | 2 | 2019 | 49 | 0.37 | Why? |
| Propanolamines | 2 | 2019 | 47 | 0.37 | Why? |
| Elasticity | 2 | 2018 | 70 | 0.37 | Why? |
| Pneumonia, Viral | 19 | 2020 | 243684 | 0.36 | Why? |
| Early Diagnosis | 5 | 2018 | 2443 | 0.36 | Why? |
| Risk Factors | 29 | 2021 | 71621 | 0.36 | Why? |
| Antirheumatic Agents | 3 | 2020 | 3023 | 0.36 | Why? |
| Italy | 18 | 2021 | 38444 | 0.36 | Why? |
| Coronavirus Infections | 19 | 2020 | 253789 | 0.36 | Why? |
| Blood Coagulation | 1 | 2021 | 2768 | 0.35 | Why? |
| Neprilysin | 2 | 2019 | 112 | 0.35 | Why? |
| Ventricular Dysfunction, Right | 3 | 2020 | 639 | 0.35 | Why? |
| Aged, 80 and over | 32 | 2021 | 88759 | 0.35 | Why? |
| Proteasome Inhibitors | 2 | 2018 | 127 | 0.34 | Why? |
| Myocarditis | 2 | 2021 | 2731 | 0.34 | Why? |
| Hypoglycemic Agents | 2 | 2019 | 2165 | 0.34 | Why? |
| Platelet Endothelial Cell Adhesion Molecule-1 | 2 | 2017 | 46 | 0.34 | Why? |
| Pulse Wave Analysis | 2 | 2019 | 221 | 0.34 | Why? |
| Anemia, Iron-Deficiency | 2 | 2020 | 210 | 0.33 | Why? |
| Quality of Life | 6 | 2020 | 9820 | 0.33 | Why? |
| Electrocardiography | 4 | 2017 | 3957 | 0.33 | Why? |
| Diabetes Mellitus | 4 | 2018 | 8207 | 0.33 | Why? |
| Patient Discharge | 5 | 2020 | 5696 | 0.32 | Why? |
| Percutaneous Coronary Intervention | 2 | 2020 | 3646 | 0.32 | Why? |
| Furosemide | 2 | 2019 | 99 | 0.32 | Why? |
| Pyridines | 3 | 2017 | 680 | 0.32 | Why? |
| Proportional Hazards Models | 9 | 2020 | 6543 | 0.32 | Why? |
| Adrenomedullin | 2 | 2019 | 217 | 0.31 | Why? |
| Troponin I | 4 | 2020 | 1298 | 0.31 | Why? |
| Oxygen Consumption | 4 | 2019 | 711 | 0.31 | Why? |
| Venous Thrombosis | 1 | 2021 | 2739 | 0.30 | Why? |
| Palliative Care | 1 | 2020 | 2665 | 0.30 | Why? |
| Heart Rate | 4 | 2019 | 1527 | 0.29 | Why? |
| Mitral Valve | 3 | 2018 | 342 | 0.29 | Why? |
| Exercise Test | 6 | 2019 | 911 | 0.29 | Why? |
| Oxygen | 2 | 2018 | 3715 | 0.29 | Why? |
| Potassium | 2 | 2018 | 325 | 0.29 | Why? |
| Natriuretic Agents | 3 | 2018 | 16 | 0.29 | Why? |
| Sodium | 2 | 2019 | 309 | 0.28 | Why? |
| Dose-Response Relationship, Drug | 10 | 2018 | 3776 | 0.28 | Why? |
| Injections, Intravenous | 4 | 2018 | 381 | 0.28 | Why? |
| Betacoronavirus | 19 | 2020 | 204454 | 0.28 | Why? |
| MicroRNAs | 1 | 2018 | 1787 | 0.28 | Why? |
| Endothelium, Vascular | 5 | 2018 | 1751 | 0.27 | Why? |
| Drug Combinations | 3 | 2019 | 3852 | 0.27 | Why? |
| Rheumatologists | 2 | 2018 | 346 | 0.27 | Why? |
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 5993 | 0.27 | Why? |
| Interleukin-6 | 2 | 2019 | 7522 | 0.27 | Why? |
| Pandemics | 21 | 2021 | 389249 | 0.27 | Why? |
| Blotting, Western | 2 | 2017 | 863 | 0.26 | Why? |
| Electronic Health Records | 1 | 2017 | 3492 | 0.26 | Why? |
| Immunosuppressive Agents | 5 | 2020 | 6331 | 0.26 | Why? |
| Cell Movement | 2 | 2017 | 695 | 0.26 | Why? |
| Pulmonary Ventilation | 2 | 2019 | 152 | 0.26 | Why? |
| Sepsis | 1 | 2020 | 3517 | 0.26 | Why? |
| Magnetic Resonance Imaging | 3 | 2018 | 6551 | 0.26 | Why? |
| Fingers | 4 | 2018 | 221 | 0.25 | Why? |
| Practice Guidelines as Topic | 7 | 2019 | 15421 | 0.25 | Why? |
| Venous Thromboembolism | 1 | 2021 | 4273 | 0.24 | Why? |
| Research Design | 5 | 2020 | 5830 | 0.24 | Why? |
| Consensus | 6 | 2019 | 6345 | 0.24 | Why? |
| Peptidyl-Dipeptidase A | 2 | 2020 | 9659 | 0.23 | Why? |
| Time Factors | 19 | 2019 | 31397 | 0.23 | Why? |
| Protease Inhibitors | 1 | 2018 | 3630 | 0.23 | Why? |
| Kidney | 5 | 2019 | 3648 | 0.23 | Why? |
| Severity of Illness Index | 17 | 2021 | 48226 | 0.23 | Why? |
| Drug Repositioning | 1 | 2020 | 5683 | 0.22 | Why? |
| Hyperkalemia | 2 | 2019 | 140 | 0.22 | Why? |
| Prospective Studies | 23 | 2020 | 43301 | 0.21 | Why? |
| Communication | 4 | 2019 | 5206 | 0.21 | Why? |
| Inflammation | 3 | 2021 | 13255 | 0.21 | Why? |
| Anti-Inflammatory Agents | 1 | 2020 | 6153 | 0.21 | Why? |
| Chlamydophila pneumoniae | 1 | 2021 | 98 | 0.21 | Why? |
| Brain | 1 | 2018 | 5133 | 0.21 | Why? |
| Pulmonary Disease, Chronic Obstructive | 1 | 2018 | 3832 | 0.20 | Why? |
| Renin | 1 | 2021 | 167 | 0.20 | Why? |
| Partial Pressure | 1 | 2020 | 279 | 0.20 | Why? |
| Cachexia | 1 | 2020 | 75 | 0.20 | Why? |
| Aldosterone | 1 | 2021 | 155 | 0.20 | Why? |
| Lipocalin-2 | 2 | 2019 | 156 | 0.20 | Why? |
| T-Lymphocytes | 1 | 2017 | 6670 | 0.20 | Why? |
| Cell Proliferation | 2 | 2017 | 1973 | 0.20 | Why? |
| Immunohistochemistry | 2 | 2017 | 2275 | 0.20 | Why? |
| Cardiomyopathy, Restrictive | 1 | 2019 | 30 | 0.19 | Why? |
| Signal Transduction | 2 | 2017 | 7207 | 0.19 | Why? |
| Coronary Angiography | 3 | 2020 | 2275 | 0.19 | Why? |
| Angiotensins | 1 | 2021 | 259 | 0.19 | Why? |
| Uterine Artery | 1 | 2018 | 36 | 0.19 | Why? |
| Ultrasonic Therapy | 1 | 2019 | 43 | 0.19 | Why? |
| Waist-Hip Ratio | 1 | 2018 | 50 | 0.19 | Why? |
| Endomyocardial Fibrosis | 1 | 2018 | 27 | 0.19 | Why? |
| Renal Insufficiency, Chronic | 3 | 2018 | 2654 | 0.19 | Why? |
| Information Dissemination | 3 | 2019 | 2986 | 0.19 | Why? |
| Sulbactam | 1 | 2018 | 37 | 0.19 | Why? |
| rac1 GTP-Binding Protein | 1 | 2018 | 32 | 0.18 | Why? |
| Synoviocytes | 1 | 2017 | 13 | 0.18 | Why? |
| Trastuzumab | 1 | 2019 | 108 | 0.18 | Why? |
| Kounis Syndrome | 1 | 2018 | 19 | 0.18 | Why? |
| Multivariate Analysis | 3 | 2020 | 5440 | 0.18 | Why? |
| Cyclophosphamide | 2 | 2018 | 387 | 0.18 | Why? |
| Sickness Impact Profile | 1 | 2018 | 56 | 0.18 | Why? |
| Ampicillin | 1 | 2018 | 73 | 0.18 | Why? |
| Nitroglycerin | 1 | 2018 | 39 | 0.18 | Why? |
| Cells, Cultured | 4 | 2018 | 5835 | 0.18 | Why? |
| Receptors, LDL | 1 | 2017 | 42 | 0.18 | Why? |
| Mycophenolic Acid | 2 | 2018 | 383 | 0.18 | Why? |
| 5-Lipoxygenase-Activating Proteins | 1 | 2017 | 4 | 0.18 | Why? |
| Mechanical Thrombolysis | 1 | 2019 | 150 | 0.18 | Why? |
| Diastole | 4 | 2018 | 168 | 0.18 | Why? |
| Atherosclerosis | 2 | 2017 | 768 | 0.18 | Why? |
| Cyclooxygenase Inhibitors | 1 | 2017 | 46 | 0.18 | Why? |
| Purinergic P1 Receptor Antagonists | 1 | 2017 | 1 | 0.18 | Why? |
| Mass Screening | 1 | 2018 | 8005 | 0.18 | Why? |
| NADPH Oxidases | 1 | 2018 | 80 | 0.18 | Why? |
| Cardiac Volume | 1 | 2017 | 10 | 0.18 | Why? |
| Case-Control Studies | 9 | 2019 | 17671 | 0.18 | Why? |
| Pneumonia | 1 | 2018 | 5652 | 0.18 | Why? |
| Nervous System Diseases | 1 | 2017 | 4092 | 0.18 | Why? |
| Receptors, Endothelin | 1 | 2017 | 13 | 0.18 | Why? |
| Hemorrhage | 3 | 2020 | 3013 | 0.17 | Why? |
| Genotype | 3 | 2019 | 4697 | 0.17 | Why? |
| Pneumonia, Mycoplasma | 1 | 2021 | 292 | 0.17 | Why? |
| S100 Calcium-Binding Protein A4 | 1 | 2017 | 14 | 0.17 | Why? |
| Health Communication | 2 | 2019 | 1120 | 0.17 | Why? |
| Tachycardia | 1 | 2019 | 239 | 0.17 | Why? |
| Chronic Disease | 4 | 2020 | 5139 | 0.17 | Why? |
| Snail Family Transcription Factors | 1 | 2017 | 20 | 0.17 | Why? |
| Hedgehog Proteins | 1 | 2017 | 39 | 0.17 | Why? |
| Matrix Metalloproteinase 12 | 1 | 2017 | 17 | 0.17 | Why? |
| Cardiac Pacing, Artificial | 1 | 2019 | 160 | 0.17 | Why? |
| Predictive Value of Tests | 8 | 2019 | 9537 | 0.17 | Why? |
| Receptors, CXCR4 | 1 | 2017 | 83 | 0.17 | Why? |
| After-Hours Care | 1 | 2018 | 82 | 0.17 | Why? |
| Microcirculation | 2 | 2018 | 447 | 0.17 | Why? |
| Fibroblast Growth Factors | 1 | 2018 | 119 | 0.17 | Why? |
| Collagen Type I | 1 | 2017 | 56 | 0.17 | Why? |
| Scientific Misconduct | 1 | 2019 | 101 | 0.17 | Why? |
| Undifferentiated Connective Tissue Diseases | 1 | 2017 | 60 | 0.17 | Why? |
| Gene Expression | 2 | 2018 | 3332 | 0.16 | Why? |
| Coronary Stenosis | 2 | 2017 | 273 | 0.16 | Why? |
| Hypertension | 2 | 2018 | 8895 | 0.16 | Why? |
| Pulmonary Artery | 2 | 2017 | 803 | 0.16 | Why? |
| Registries | 5 | 2021 | 12327 | 0.16 | Why? |
| Blood Gas Analysis | 1 | 2020 | 893 | 0.16 | Why? |
| Actins | 1 | 2017 | 108 | 0.16 | Why? |
| Cardiomyopathy, Hypertrophic | 1 | 2019 | 193 | 0.16 | Why? |
| Adult | 30 | 2019 | 244371 | 0.16 | Why? |
| Urokinase-Type Plasminogen Activator | 1 | 2017 | 62 | 0.16 | Why? |
| Integrins | 1 | 2018 | 158 | 0.16 | Why? |
| Doxorubicin | 1 | 2019 | 313 | 0.16 | Why? |
| Skin Tests | 1 | 2018 | 229 | 0.16 | Why? |
| Nervous System | 1 | 2019 | 303 | 0.16 | Why? |
| Communications Media | 1 | 2019 | 151 | 0.16 | Why? |
| Cardio-Renal Syndrome | 1 | 2018 | 68 | 0.16 | Why? |
| Autoantibodies | 4 | 2021 | 2094 | 0.16 | Why? |
| Cadherins | 1 | 2017 | 145 | 0.16 | Why? |
| CD3 Complex | 1 | 2017 | 237 | 0.16 | Why? |
| Treatment Refusal | 1 | 2019 | 211 | 0.16 | Why? |
| Body Mass Index | 3 | 2019 | 4306 | 0.16 | Why? |
| Lung Diseases, Fungal | 1 | 2017 | 167 | 0.16 | Why? |
| Dermatomyositis | 1 | 2019 | 193 | 0.16 | Why? |
| Wound Healing | 2 | 2018 | 424 | 0.16 | Why? |
| Proprotein Convertase 9 | 1 | 2017 | 141 | 0.16 | Why? |
| Catheterization, Swan-Ganz | 1 | 2015 | 30 | 0.16 | Why? |
| Retrospective Studies | 22 | 2021 | 105322 | 0.16 | Why? |
| Hashimoto Disease | 1 | 2017 | 74 | 0.16 | Why? |
| Intercellular Signaling Peptides and Proteins | 1 | 2018 | 245 | 0.16 | Why? |
| Cardiac Imaging Techniques | 1 | 2019 | 357 | 0.16 | Why? |
| Methotrexate | 2 | 2018 | 471 | 0.16 | Why? |
| Lipoproteins, HDL | 1 | 2017 | 154 | 0.15 | Why? |
| Carbazoles | 1 | 2017 | 120 | 0.15 | Why? |
| Research Subjects | 1 | 2018 | 178 | 0.15 | Why? |
| Mucin-1 | 1 | 2019 | 277 | 0.15 | Why? |
| Bleomycin | 1 | 2017 | 195 | 0.15 | Why? |
| Glomerular Filtration Rate | 2 | 2019 | 1262 | 0.15 | Why? |
| Nerve Tissue Proteins | 1 | 2018 | 319 | 0.15 | Why? |
| Spirometry | 1 | 2019 | 524 | 0.15 | Why? |
| Clinical Decision-Making | 3 | 2018 | 3755 | 0.15 | Why? |
| Etanercept | 1 | 2017 | 162 | 0.15 | Why? |
| Anticholesteremic Agents | 1 | 2017 | 186 | 0.15 | Why? |
| Mesenchymal Stem Cell Transplantation | 2 | 2017 | 1322 | 0.15 | Why? |
| Blood Pressure Determination | 1 | 2019 | 450 | 0.15 | Why? |
| Repressor Proteins | 1 | 2017 | 232 | 0.15 | Why? |
| Transforming Growth Factor beta1 | 1 | 2017 | 204 | 0.15 | Why? |
| Serum | 1 | 2017 | 294 | 0.14 | Why? |
| Osteoarthritis | 1 | 2017 | 205 | 0.14 | Why? |
| Cardiorespiratory Fitness | 1 | 2019 | 313 | 0.14 | Why? |
| Troponin | 1 | 2021 | 1058 | 0.14 | Why? |
| Methylprednisolone | 2 | 2018 | 2107 | 0.14 | Why? |
| Myocardial Infarction | 4 | 2018 | 3361 | 0.14 | Why? |
| Microscopy, Fluorescence | 1 | 2015 | 335 | 0.14 | Why? |
| Fluorescent Antibody Technique | 1 | 2017 | 835 | 0.14 | Why? |
| Protective Factors | 1 | 2020 | 1720 | 0.14 | Why? |
| Kidney Function Tests | 2 | 2017 | 520 | 0.14 | Why? |
| Inservice Training | 1 | 2018 | 477 | 0.14 | Why? |
| Incidence | 5 | 2020 | 25622 | 0.14 | Why? |
| Epidemiologic Methods | 1 | 2018 | 392 | 0.14 | Why? |
| Walking | 1 | 2019 | 442 | 0.14 | Why? |
| Drug Costs | 1 | 2018 | 313 | 0.13 | Why? |
| Delivery of Health Care | 1 | 2021 | 15909 | 0.13 | Why? |
| Down-Regulation | 1 | 2020 | 1416 | 0.13 | Why? |
| Receptors, Cell Surface | 1 | 2018 | 586 | 0.13 | Why? |
| Health Knowledge, Attitudes, Practice | 5 | 2019 | 8811 | 0.13 | Why? |
| Autoimmunity | 1 | 2021 | 841 | 0.13 | Why? |
| Randomized Controlled Trials as Topic | 6 | 2019 | 10649 | 0.13 | Why? |
| Edema | 1 | 2017 | 333 | 0.13 | Why? |
| Hand | 1 | 2018 | 449 | 0.13 | Why? |
| Clinical Trials, Phase II as Topic | 1 | 2017 | 801 | 0.13 | Why? |
| Prednisone | 1 | 2018 | 652 | 0.13 | Why? |
| Spondylitis, Ankylosing | 1 | 2016 | 231 | 0.13 | Why? |
| Mast Cells | 1 | 2017 | 370 | 0.13 | Why? |
| Radiotherapy | 1 | 2019 | 608 | 0.13 | Why? |
| Receptors, Transforming Growth Factor beta | 1 | 2012 | 20 | 0.13 | Why? |
| Cardiology Service, Hospital | 1 | 2020 | 602 | 0.13 | Why? |
| Treatment Failure | 1 | 2019 | 2106 | 0.13 | Why? |
| Intracellular Signaling Peptides and Proteins | 1 | 2015 | 334 | 0.12 | Why? |
| Adalimumab | 1 | 2017 | 389 | 0.12 | Why? |
| Antineoplastic Agents | 2 | 2019 | 3550 | 0.12 | Why? |
| Genetic Therapy | 1 | 2017 | 409 | 0.12 | Why? |
| Anxiety | 1 | 2018 | 17311 | 0.12 | Why? |
| Video Recording | 1 | 2018 | 786 | 0.12 | Why? |
| Pre-Eclampsia | 1 | 2018 | 599 | 0.12 | Why? |
| Cohort Studies | 11 | 2021 | 36005 | 0.12 | Why? |
| Neoplasms | 2 | 2020 | 17251 | 0.12 | Why? |
| Warfarin | 1 | 2016 | 402 | 0.11 | Why? |
| Patient Care Management | 2 | 2020 | 1514 | 0.11 | Why? |
| Phosphorylation | 1 | 2015 | 1060 | 0.11 | Why? |
| Education, Medical, Continuing | 1 | 2018 | 638 | 0.11 | Why? |
| Neoplasm Proteins | 1 | 2017 | 501 | 0.11 | Why? |
| Heart Valve Prosthesis | 1 | 2017 | 533 | 0.11 | Why? |
| Diagnostic Tests, Routine | 2 | 2020 | 2643 | 0.11 | Why? |
| Mice, Knockout | 1 | 2017 | 1815 | 0.11 | Why? |
| Medical Informatics | 1 | 2019 | 648 | 0.11 | Why? |
| Therapies, Investigational | 1 | 2014 | 235 | 0.11 | Why? |
| Thiazoles | 1 | 2016 | 496 | 0.11 | Why? |
| Multicenter Studies as Topic | 1 | 2018 | 2437 | 0.11 | Why? |
| Factor Xa Inhibitors | 1 | 2016 | 490 | 0.11 | Why? |
| Administration, Intravenous | 3 | 2020 | 1115 | 0.11 | Why? |
| Aortic Valve | 1 | 2017 | 664 | 0.11 | Why? |
| Outpatients | 3 | 2020 | 3417 | 0.11 | Why? |
| Dogs | 1 | 2018 | 2529 | 0.11 | Why? |
| Anticoagulants | 3 | 2021 | 9563 | 0.11 | Why? |
| Antiphospholipid Syndrome | 1 | 2017 | 533 | 0.11 | Why? |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2019 | 1510 | 0.10 | Why? |
| Program Development | 1 | 2017 | 1089 | 0.10 | Why? |
| Consumer Health Information | 1 | 2019 | 750 | 0.10 | Why? |
| Immune System | 1 | 2020 | 1479 | 0.10 | Why? |
| NF-kappa B | 1 | 2017 | 1301 | 0.10 | Why? |
| Shock, Septic | 1 | 2020 | 1313 | 0.10 | Why? |
| Myocardial Ischemia | 1 | 2017 | 781 | 0.10 | Why? |
| Cardiovascular System | 1 | 2018 | 750 | 0.10 | Why? |
| Symptom Assessment | 3 | 2018 | 4967 | 0.10 | Why? |
| Renal Insufficiency | 1 | 2017 | 810 | 0.10 | Why? |
| Molecular Targeted Therapy | 1 | 2018 | 1579 | 0.10 | Why? |
| Attitude | 1 | 2019 | 1481 | 0.10 | Why? |
| Combined Modality Therapy | 1 | 2018 | 3395 | 0.10 | Why? |
| Activities of Daily Living | 1 | 2018 | 1530 | 0.09 | Why? |
| Ultrasonography | 3 | 2021 | 4409 | 0.09 | Why? |
| Income | 1 | 2018 | 1564 | 0.09 | Why? |
| Endovascular Procedures | 1 | 2019 | 1302 | 0.09 | Why? |
| Vascular Diseases | 1 | 2018 | 846 | 0.09 | Why? |
| Polymorphism, Single Nucleotide | 3 | 2017 | 3607 | 0.09 | Why? |
| Enzyme-Linked Immunosorbent Assay | 4 | 2019 | 7868 | 0.09 | Why? |
| Critical Pathways | 1 | 2019 | 1587 | 0.09 | Why? |
| Multiple Myeloma | 1 | 2018 | 1064 | 0.09 | Why? |
| Social Media | 3 | 2019 | 5798 | 0.09 | Why? |
| Frailty | 1 | 2020 | 1432 | 0.09 | Why? |
| Mortality | 4 | 2018 | 7132 | 0.09 | Why? |
| Transcatheter Aortic Valve Replacement | 1 | 2017 | 839 | 0.09 | Why? |
| Age Factors | 3 | 2020 | 21039 | 0.09 | Why? |
| Survival Analysis | 3 | 2017 | 7592 | 0.09 | Why? |
| Anaphylaxis | 1 | 2018 | 940 | 0.09 | Why? |
| RNA Polymerase III | 2 | 2018 | 18 | 0.09 | Why? |
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 9335 | 0.09 | Why? |
| Civil Defense | 1 | 2020 | 1687 | 0.09 | Why? |
| Biomedical Research | 2 | 2019 | 5270 | 0.09 | Why? |
| Cost-Benefit Analysis | 1 | 2018 | 2259 | 0.09 | Why? |
| Lung | 5 | 2021 | 31049 | 0.09 | Why? |
| Needs Assessment | 1 | 2018 | 2352 | 0.09 | Why? |
| Heparin | 1 | 2020 | 2600 | 0.09 | Why? |
| DNA Topoisomerases, Type I | 2 | 2018 | 86 | 0.08 | Why? |
| Growth Differentiation Factor 15 | 2 | 2018 | 89 | 0.08 | Why? |
| Recovery of Function | 1 | 2018 | 2461 | 0.08 | Why? |
| Proteome | 1 | 2017 | 1812 | 0.08 | Why? |
| Fibrinolytic Agents | 1 | 2019 | 1702 | 0.08 | Why? |
| Pregnancy Complications | 1 | 2018 | 1388 | 0.08 | Why? |
| Preoperative Care | 1 | 2017 | 1515 | 0.08 | Why? |
| Respiratory Function Tests | 3 | 2019 | 1755 | 0.08 | Why? |
| Pulmonary Fibrosis | 1 | 2017 | 1068 | 0.08 | Why? |
| Forecasting | 2 | 2019 | 4492 | 0.08 | Why? |
| Thrombolytic Therapy | 1 | 2019 | 2218 | 0.08 | Why? |
| Thromboembolism | 1 | 2020 | 2101 | 0.08 | Why? |
| Immunity, Cellular | 1 | 2020 | 3614 | 0.08 | Why? |
| Fatigue | 1 | 2018 | 2479 | 0.08 | Why? |
| Time-to-Treatment | 2 | 2020 | 5883 | 0.08 | Why? |
| Cytokines | 2 | 2020 | 15010 | 0.08 | Why? |
| Social Determinants of Health | 1 | 2018 | 1757 | 0.08 | Why? |
| Truth Disclosure | 2 | 2019 | 196 | 0.08 | Why? |
| Membrane Glycoproteins | 1 | 2015 | 2273 | 0.08 | Why? |
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 1454 | 0.08 | Why? |
| Antibodies, Antinuclear | 2 | 2019 | 234 | 0.08 | Why? |
| Ventricular Function, Right | 2 | 2020 | 388 | 0.08 | Why? |
| Inflammation Mediators | 1 | 2017 | 2654 | 0.08 | Why? |
| Mice, Inbred C57BL | 1 | 2017 | 5542 | 0.08 | Why? |
| Periodicals as Topic | 1 | 2019 | 1492 | 0.08 | Why? |
| Prevalence | 4 | 2020 | 25773 | 0.08 | Why? |
| Length of Stay | 2 | 2020 | 11042 | 0.07 | Why? |
| Nuclear Proteins | 2 | 2018 | 321 | 0.07 | Why? |
| Health Status | 1 | 2018 | 3259 | 0.07 | Why? |
| Smoking | 1 | 2018 | 3358 | 0.07 | Why? |
| Internationality | 1 | 2018 | 3297 | 0.07 | Why? |
| Pregnancy | 4 | 2019 | 23879 | 0.07 | Why? |
| Death | 2 | 2018 | 334 | 0.07 | Why? |
| Psoriasis | 1 | 2018 | 1739 | 0.07 | Why? |
| Netherlands | 3 | 2018 | 3533 | 0.07 | Why? |
| United States | 8 | 2017 | 46150 | 0.07 | Why? |
| Transplant Recipients | 1 | 2020 | 4982 | 0.07 | Why? |
| Patient Safety | 4 | 2020 | 4885 | 0.07 | Why? |
| Health Status Disparities | 2 | 2018 | 4072 | 0.07 | Why? |
| Cardiac Surgical Procedures | 1 | 2017 | 1931 | 0.06 | Why? |
| Adrenal Cortex Hormones | 1 | 2020 | 6537 | 0.06 | Why? |
| Algorithms | 2 | 2017 | 7346 | 0.06 | Why? |
| Practice Patterns, Physicians' | 2 | 2019 | 4927 | 0.06 | Why? |
| Clinical Competence | 1 | 2018 | 3263 | 0.06 | Why? |
| Rheumatic Diseases | 1 | 2018 | 2675 | 0.06 | Why? |
| Animals | 5 | 2018 | 78931 | 0.06 | Why? |
| Coronary Artery Disease | 1 | 2017 | 2570 | 0.06 | Why? |
| Postoperative Complications | 1 | 2020 | 5861 | 0.06 | Why? |
| Referral and Consultation | 1 | 2018 | 4816 | 0.06 | Why? |
| Genetic Predisposition to Disease | 2 | 2017 | 4027 | 0.06 | Why? |
| Odds Ratio | 3 | 2018 | 5861 | 0.06 | Why? |
| Linear Models | 2 | 2018 | 1914 | 0.06 | Why? |
| ROC Curve | 3 | 2019 | 6024 | 0.06 | Why? |
| Surgical Procedures, Operative | 1 | 2017 | 2662 | 0.06 | Why? |
| Protein Binding | 1 | 2018 | 11430 | 0.05 | Why? |
| Databases, Factual | 4 | 2018 | 6248 | 0.05 | Why? |
| Liver Diseases | 1 | 2017 | 2698 | 0.05 | Why? |
| Host-Pathogen Interactions | 1 | 2021 | 11041 | 0.05 | Why? |
| Coinfection | 1 | 2021 | 6820 | 0.05 | Why? |
| Cross-Sectional Studies | 5 | 2020 | 53120 | 0.05 | Why? |
| Prospidium | 1 | 2019 | 1 | 0.05 | Why? |
| Patient Admission | 1 | 2017 | 5250 | 0.05 | Why? |
| DNA Topoisomerases | 1 | 2018 | 2 | 0.05 | Why? |
| Tomography, X-Ray Computed | 3 | 2020 | 25144 | 0.05 | Why? |
| Activating Transcription Factor 2 | 1 | 2018 | 11 | 0.05 | Why? |
| CD18 Antigens | 1 | 2018 | 19 | 0.05 | Why? |
| Adenosine A1 Receptor Antagonists | 1 | 2018 | 1 | 0.05 | Why? |
| Receptors, Interleukin-1 Type I | 1 | 2018 | 18 | 0.05 | Why? |
| Heart Auscultation | 1 | 2018 | 6 | 0.05 | Why? |
| Mycoplasma pneumoniae | 1 | 2021 | 233 | 0.05 | Why? |
| Stroke | 3 | 2018 | 8839 | 0.05 | Why? |
| Marketing of Health Services | 1 | 2019 | 68 | 0.05 | Why? |
| Public Opinion | 2 | 2019 | 1165 | 0.05 | Why? |
| Hyperemia | 1 | 2018 | 62 | 0.05 | Why? |
| Disease Models, Animal | 1 | 2017 | 10998 | 0.05 | Why? |
| Logistic Models | 3 | 2018 | 9089 | 0.05 | Why? |
| Potentiometry | 1 | 2017 | 11 | 0.05 | Why? |
| beta Catenin | 1 | 2018 | 78 | 0.04 | Why? |
| Hepatitis A Virus Cellular Receptor 1 | 1 | 2019 | 86 | 0.04 | Why? |
| Coronary Vasospasm | 1 | 2018 | 36 | 0.04 | Why? |
| Positive Regulatory Domain I-Binding Factor 1 | 1 | 2017 | 12 | 0.04 | Why? |
| Contraindications, Drug | 1 | 2019 | 281 | 0.04 | Why? |
| Coccidioidomycosis | 1 | 2017 | 47 | 0.04 | Why? |
| Transcriptional Activation | 1 | 2018 | 196 | 0.04 | Why? |
| Reproducibility of Results | 4 | 2018 | 11304 | 0.04 | Why? |
| Transferrin | 1 | 2017 | 90 | 0.04 | Why? |
| Acute-Phase Proteins | 1 | 2018 | 177 | 0.04 | Why? |
| Antibodies, Monoclonal | 1 | 2017 | 8041 | 0.04 | Why? |
| Spectroscopy, Near-Infrared | 1 | 2018 | 137 | 0.04 | Why? |
| beta-Lactamase Inhibitors | 1 | 2018 | 104 | 0.04 | Why? |
| Interferon-Induced Helicase, IFIH1 | 1 | 2019 | 245 | 0.04 | Why? |
| Puerperal Disorders | 1 | 2019 | 151 | 0.04 | Why? |
| Histoplasmosis | 1 | 2017 | 83 | 0.04 | Why? |
| Mice | 1 | 2017 | 21357 | 0.04 | Why? |
| Acute Kidney Injury | 1 | 2017 | 5762 | 0.04 | Why? |
| Interleukin-1 Receptor-Like 1 Protein | 1 | 2017 | 92 | 0.04 | Why? |
| Hand Strength | 1 | 2018 | 202 | 0.04 | Why? |
| Vital Capacity | 1 | 2018 | 399 | 0.04 | Why? |
| Diabetes Mellitus, Type 2 | 1 | 2018 | 6166 | 0.04 | Why? |
| Proteasome Endopeptidase Complex | 1 | 2018 | 249 | 0.04 | Why? |
| Cryptococcosis | 1 | 2017 | 97 | 0.04 | Why? |
| Receptor, Angiotensin, Type 1 | 1 | 2017 | 160 | 0.04 | Why? |
| Evaluation Studies as Topic | 1 | 2018 | 391 | 0.04 | Why? |
| Conflict of Interest | 1 | 2019 | 175 | 0.04 | Why? |
| Alberta | 1 | 2017 | 375 | 0.04 | Why? |
| Posture | 1 | 2018 | 199 | 0.04 | Why? |
| Heterozygote | 1 | 2017 | 249 | 0.04 | Why? |
| Homozygote | 1 | 2017 | 230 | 0.04 | Why? |
| Galectin 3 | 1 | 2017 | 76 | 0.04 | Why? |
| Bioprosthesis | 1 | 2017 | 126 | 0.04 | Why? |
| Vasodilation | 1 | 2018 | 258 | 0.04 | Why? |
| Galectins | 1 | 2017 | 109 | 0.04 | Why? |
| Cystatin C | 1 | 2017 | 125 | 0.04 | Why? |
| Prosthesis Failure | 1 | 2017 | 195 | 0.04 | Why? |
| Observer Variation | 1 | 2018 | 622 | 0.04 | Why? |
| Walk Test | 1 | 2019 | 461 | 0.04 | Why? |
| Ubiquitin | 1 | 2018 | 243 | 0.04 | Why? |
| Death Certificates | 1 | 2017 | 130 | 0.04 | Why? |
| Prosthesis Design | 1 | 2018 | 594 | 0.04 | Why? |
| Medical Overuse | 1 | 2018 | 146 | 0.04 | Why? |
| Diagnosis, Differential | 2 | 2020 | 7220 | 0.04 | Why? |
| Forced Expiratory Volume | 1 | 2018 | 632 | 0.04 | Why? |
| Respiration, Artificial | 1 | 2020 | 22116 | 0.04 | Why? |
| Hypokalemia | 1 | 2017 | 195 | 0.04 | Why? |
| Electrolytes | 1 | 2015 | 103 | 0.04 | Why? |
| Respiratory Sounds | 1 | 2018 | 294 | 0.04 | Why? |
| Risk | 2 | 2017 | 5288 | 0.04 | Why? |
| Myocytes, Cardiac | 1 | 2021 | 804 | 0.04 | Why? |
| Pain Measurement | 1 | 2018 | 533 | 0.03 | Why? |
| Mentors | 1 | 2018 | 372 | 0.03 | Why? |
| Physicians, Primary Care | 1 | 2018 | 298 | 0.03 | Why? |
| Focus Groups | 1 | 2018 | 811 | 0.03 | Why? |
| Muscle Weakness | 1 | 2018 | 406 | 0.03 | Why? |
| Spatial Analysis | 1 | 2020 | 878 | 0.03 | Why? |
| Access to Information | 1 | 2019 | 483 | 0.03 | Why? |
| European Union | 1 | 2018 | 565 | 0.03 | Why? |
| Dyspnea | 2 | 2018 | 3847 | 0.03 | Why? |
| Drug Therapy, Combination | 2 | 2018 | 7268 | 0.03 | Why? |
| Early Medical Intervention | 1 | 2017 | 487 | 0.03 | Why? |
| Checklist | 1 | 2019 | 714 | 0.03 | Why? |
| China | 1 | 2020 | 50654 | 0.03 | Why? |
| Gestational Age | 1 | 2018 | 1488 | 0.03 | Why? |
| Pneumonia, Pneumocystis | 1 | 2017 | 322 | 0.03 | Why? |
| Blood Proteins | 1 | 2017 | 551 | 0.03 | Why? |
| Smokers | 1 | 2018 | 550 | 0.03 | Why? |
| Informed Consent | 1 | 2020 | 890 | 0.03 | Why? |
| Cell Survival | 1 | 2018 | 1581 | 0.03 | Why? |
| Longitudinal Studies | 2 | 2018 | 9893 | 0.03 | Why? |
| Pulmonary Aspergillosis | 1 | 2017 | 408 | 0.03 | Why? |
| Familial Primary Pulmonary Hypertension | 1 | 2012 | 68 | 0.03 | Why? |
| Gene Frequency | 1 | 2017 | 1210 | 0.03 | Why? |
| Sex Factors | 2 | 2020 | 11014 | 0.03 | Why? |
| Mental Health | 1 | 2018 | 15770 | 0.03 | Why? |
| Meta-Analysis as Topic | 1 | 2018 | 1289 | 0.03 | Why? |
| Clinical Trials, Phase III as Topic | 1 | 2015 | 782 | 0.03 | Why? |
| Respiration Disorders | 1 | 2017 | 526 | 0.03 | Why? |
| HLA Antigens | 1 | 2017 | 830 | 0.03 | Why? |
| Ontario | 1 | 2017 | 1966 | 0.03 | Why? |
| Cardiac Catheterization | 1 | 2018 | 882 | 0.03 | Why? |
| Stents | 1 | 2018 | 916 | 0.03 | Why? |
| Area Under Curve | 1 | 2018 | 2564 | 0.03 | Why? |
| Regression Analysis | 1 | 2018 | 2484 | 0.03 | Why? |
| Communicable Disease Control | 1 | 2020 | 29620 | 0.03 | Why? |
| Shock, Cardiogenic | 1 | 2017 | 700 | 0.03 | Why? |
| Safety | 1 | 2018 | 1583 | 0.03 | Why? |
| DNA Mutational Analysis | 1 | 2012 | 581 | 0.02 | Why? |
| Autopsy | 1 | 2021 | 3495 | 0.02 | Why? |
| Genome-Wide Association Study | 1 | 2017 | 1648 | 0.02 | Why? |
| United States Food and Drug Administration | 1 | 2017 | 1276 | 0.02 | Why? |
| Biopsy | 1 | 2018 | 2811 | 0.02 | Why? |
| Precision Medicine | 1 | 2018 | 1477 | 0.02 | Why? |
| Drug Approval | 1 | 2017 | 1325 | 0.02 | Why? |
| Leukocytes, Mononuclear | 1 | 2017 | 2115 | 0.02 | Why? |
| Disease-Free Survival | 1 | 2012 | 1654 | 0.02 | Why? |
| Recurrence | 1 | 2017 | 3675 | 0.02 | Why? |
| Pulmonary Gas Exchange | 1 | 2010 | 414 | 0.02 | Why? |
| Cost of Illness | 1 | 2018 | 1903 | 0.02 | Why? |
| Statistics as Topic | 1 | 2009 | 370 | 0.02 | Why? |
| Perioperative Care | 1 | 2017 | 1329 | 0.02 | Why? |
| Quality Improvement | 1 | 2019 | 2435 | 0.02 | Why? |
| Health Surveys | 1 | 2018 | 2841 | 0.02 | Why? |
| Review Literature as Topic | 1 | 2009 | 387 | 0.02 | Why? |
| Qualitative Research | 1 | 2018 | 4337 | 0.02 | Why? |
| Asymptomatic Diseases | 1 | 2018 | 3444 | 0.02 | Why? |
| Republic of Korea | 1 | 2018 | 5858 | 0.02 | Why? |
| Lung Diseases | 1 | 2018 | 2361 | 0.02 | Why? |
| Acute Coronary Syndrome | 1 | 2018 | 2107 | 0.02 | Why? |
| Japan | 1 | 2017 | 6653 | 0.02 | Why? |
| Autoimmune Diseases | 1 | 2017 | 1996 | 0.02 | Why? |
| Carbon Dioxide | 1 | 2010 | 917 | 0.02 | Why? |
| Computer Simulation | 1 | 2018 | 4982 | 0.02 | Why? |
| Gastrointestinal Diseases | 1 | 2018 | 2580 | 0.02 | Why? |
| Young Adult | 3 | 2019 | 93724 | 0.02 | Why? |
| Immunoassay | 1 | 2018 | 4485 | 0.01 | Why? |
| Tertiary Care Centers | 1 | 2019 | 8248 | 0.01 | Why? |
| France | 1 | 2017 | 12074 | 0.01 | Why? |
| Healthcare Disparities | 1 | 2018 | 3893 | 0.01 | Why? |
| C-Reactive Protein | 1 | 2017 | 7972 | 0.01 | Why? |
| Social Isolation | 1 | 2020 | 5932 | 0.01 | Why? |
| Inpatients | 1 | 2014 | 5161 | 0.01 | Why? |
| Adolescent | 2 | 2019 | 86841 | 0.01 | Why? |
| United Kingdom | 1 | 2017 | 18046 | 0.01 | Why? |
| Thrombosis | 1 | 2018 | 7504 | 0.01 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.01 | Why? |
| Emergency Service, Hospital | 1 | 2018 | 14232 | 0.01 | Why? |
| Ambulatory Care | 1 | 2009 | 4947 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2018 | 43792 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2009 | 22971 | 0.01 | Why? |
| Antiviral Agents | 1 | 2020 | 41703 | 0.01 | Why? |